Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00790062 · ClinicalTrials.gov registry record · Phase 4
Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT
A Phase 4 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,798
- Enrollment target
NCT00790062 is a Phase 4 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 1,798 participants.
The verdict
NCT00790062, a Phase 4 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,798 participants
- Enrollment target
Study Summary
This is a double-blind 3-arm randomized clinical trial to determine whether higher dose oxytocin regimens (compared to the standard regimen) reduce the frequency of uterine atony and postpartum hemorrhage after vaginal delivery. Uterine atony is a loss of tone in the uterine musculature which can cause acute postpartum hemorrhage, which is the major cause of maternal mortality worldwide. Oxytocin is routinely administered postpartum in the US and effectively reduces uterine atony. The optimal dose of oxytocin for vaginal delivery is not known.
Interventions
- DRUG Oxytocin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,798 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00790062
The ClinicalTrials.gov registry entry for NCT00790062 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,798 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxytocin is the first listed.
NCT00790062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00790062 about?
NCT00790062 is a clinical study titled "Oxytocin Regimen to Prevent Atony and Postpartum Hemorrhage During Vaginal Delivery: 3-arm RCT". This is a double-blind 3-arm randomized clinical trial to determine whether higher dose oxytocin regimens (compared to the standard regimen) reduce the frequency of uterine atony and postpartum hemorrhage after vaginal delivery. Uterine atony is a loss of tone in the uterine musculature which can ca...
What is the current status of trial NCT00790062?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,798 participants. The study started on 2008-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00790062?
The interventions under investigation include: Oxytocin (DRUG).
Who is sponsoring clinical trial NCT00790062?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.